Trial Profile
Two Cycles of Pad Combination (Ps-341/Bortezomib, Adriamycin, and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PADinMM
- 14 Jun 2011 New trial record